Skip to main content

Table 1 Patients demographic and baseline characteristics

From: Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero’s adalimumab (Mabura®, Hetero Biopharma Ltd.) and reference adalimumab (Humira®, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy

CharacteristicsTest (n = 112)Reference (n = 56)p value
Gender
 Male22 (19.6)9 (16.1)0.675*
 Female90 (80.4)47 (83.9)
Age (years)43.90 ± 11.3740.8 ± 9.990.088**
Height (cm)158.27 ± 7.03156.90 ± 7.220.240**
Weight (Kg)58.58 ± 11.5256.76 ± 9.470.310**
BMI (Kg/m2)23.42 ± 4.8823.08 ± 3.740.646**
Race
 Asian112 (100)56 (100)0.557*
RA Score8.969.08NA
ACR Response Criteria
 Swollen Joint Count (SJC)24.3 ± 13.2423.8 ± 11.620.794
 Tender Joint Count (TJC)29.1 ± 12.9929.9 ± 11.950.695
 Patient’s Assessment of Pain80.7 ± 8.7780.6 ± 10.020.957
 Patient’s Global Assessment of Disease Activity79.3 ± 9.9076.8 ± 11.580.162
 Physician’s Global Assessment of Disease Activity76.6 ± 8.8576.6 ± 9.540.995
 Patient’s assessment of Physical Function2.0 ± 0.401.9 ± 0.450.077
 Acute Phase Reactant (CRP (mg/dL))24.8 ± 28.6122.7 ± 22.640.632
DAS28-CRP6.6 ± 0.846.5 ± 0.830.336
HAQ-DI2.0 ± 0.401.9 ± 0.450.0775
IL-6 level15.9 ± 15.7818.0 ± 20.870.705
  1. Data are shown as mean ± SD or n (%); *p values are obtained by performing Fisher’s exact test; **p values are obtained by performing t-test; DAS28-CRP Disease activity score in 28 joints C-reactive protein; HAQ-DI Health assessment questionnaire disease index, CRP C-reactive protein; IL-6 Interleukin-6, TNF-alpha Tumor necrosis factor-alpha; NA: not applicable